Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study

Abstract

Gemcitabine is a key drug for the treatment of pancreatic cancer; however, with its limitation in clinical benefits, the development of another potent therapeutic is necessary. Vascular endothelial growth factor receptor 2 is an essential target for tumor angiogenesis, and we have conducted a phase I clinical trial using gemcitabine and vascular endothelial… (More)
DOI: 10.1111/cas.12674

Topics

Cite this paper

@inproceedings{Yamaue2015RandomizedPI, title={Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study}, author={Hiroki Yamaue and Takuya Tsunoda and Masaji Tani and Motoki Miyazawa and Kenji Yamao and Nobumasa Mizuno and Takuji Okusaka and Hideki Ueno and Narikazu Boku and Akira Fukutomi and Hiroshi Ishii and Shinichi Ohkawa and Masayuki Furukawa and Hiroyuki Maguchi and Masafumi Ikeda and Yosuke Togashi and Kazuto Nishio and Yasuo Ohashi}, booktitle={Cancer science}, year={2015} }